{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:35:36Z","timestamp":1792985736298,"version":"4.5.0"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.critrevonc.2025.104962","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:07:08Z","timestamp":1758589628000},"page":"104962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Comprehensive analysis of BRCA1\/2 mutations, \u201cBRCAness\u201d and PARP inhibitors in melanoma"],"prefix":"10.1016","volume":"215","author":[{"given":"Dimitrios","family":"Stylianakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Stylianakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris Annette","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serafina","family":"Martella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Tziotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpamali","family":"De Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Giannakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Solinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerina","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2025.104962_bib1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.21037\/apm-22-1432","article-title":"Melanoma\u2014the therapeutic considerations in clinical practice","volume":"12","author":"Adeleke","year":"2023","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.critrevonc.2025.104962_bib2","article-title":"PARP inhibition as a treatment modality in melanoma: what we have learned and what we hope to achieve","author":"Anaeme","year":"2024","journal-title":"Prepr. Org."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104962_bib3","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104962_bib4","article-title":"Molecular landscape of hereditary melanoma","volume":"164","author":"Arnaut","year":"2021","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104962_bib5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104962_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103208","article-title":"Melanoma of unknown primary: new perspectives for an old story","volume":"158","author":"Boussios","year":"2021","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104962_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/diagnostics9020055","article-title":"PARP inhibitors in ovarian cancer: the route to \"ithaca\"","volume":"9","author":"Boussios","year":"2019","journal-title":"Diagnostics"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104962_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/jpm10020041","article-title":"Wise management of ovarian cancer: on the cutting edge","volume":"10","author":"Boussios","year":"2020","journal-title":"J. Pers. Med."},{"issue":"7035","key":"10.1016\/j.critrevonc.2025.104962_bib9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104962_bib10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrc3537","article-title":"End-joining, translocations and cancer","volume":"13","author":"Bunting","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104962_bib11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.tcb.2019.06.005","article-title":"Defining and modulating 'BRCAness","volume":"29","author":"Byrum","year":"2019","journal-title":"Trends Cell Biol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104962_bib12","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2025.104962_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Carvajal","year":"2017","journal-title":"Clin. Ophthalmol."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104962_bib14","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104962_bib15","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI123319","article-title":"PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer","volume":"129","author":"Chabanon","year":"2019","journal-title":"J. Clin. Invest"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104962_bib16","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.3390\/cancers13184520","article-title":"PARP inhibitors in Melanoma\u2014An expanding therapeutic option?","volume":"13","author":"Chan","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104962_bib17","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104962_bib18","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104962_bib19","series-title":"DNA Repair and Human Disease","first-page":"29","article-title":"BRCA2: safeguarding the genome through homologous recombination","author":"Christ","year":"2007"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104962_bib20","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1158\/0008-5472.CAN-10-3997","article-title":"Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth","volume":"71","author":"Civenni","year":"2011","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104962_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","article-title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","volume":"19","author":"Copson","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104962_bib22","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104962_bib23","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"46","key":"10.1016\/j.critrevonc.2025.104962_bib24","doi-asserted-by":"crossref","first-page":"75551","DOI":"10.18632\/oncotarget.12270","article-title":"PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas","volume":"7","author":"Czyz","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104962_bib25","article-title":"Advances in adoptive T-cell therapy for metastatic melanoma","volume":"71","author":"Das","year":"2023","journal-title":"Curr. Res. Transl. Med."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104962_bib26","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1002\/cncr.31345","article-title":"Melanoma: what do all the mutations mean?","volume":"124","author":"Davis","year":"2018","journal-title":"Cancer"},{"issue":"50","key":"10.1016\/j.critrevonc.2025.104962_bib27","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1073\/pnas.1512832112","article-title":"STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity","volume":"112","author":"Demaria","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2025.104962_bib28","first-page":"1","article-title":"PARP inhibition elicits STING-dependent antitumor immunity in BRCAness models of melanoma","volume":"9","author":"Ding","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104962_bib29","article-title":"Title: efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","author":"Domchek","year":"2020","journal-title":"J. Oncol."},{"issue":"7035","key":"10.1016\/j.critrevonc.2025.104962_bib30","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104962_bib31","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1158\/0008-5472.CAN-07-2538","article-title":"The promyelocytic leukemia zinc Finger\u2013MicroRNA-221\/-222 pathway controls melanoma progression through multiple oncogenic mechanisms","volume":"68","author":"Felicetti","year":"2008","journal-title":"Cancer Res."},{"issue":"9510","key":"10.1016\/j.critrevonc.2025.104962_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(06)68226-3","article-title":"Male breast cancer","volume":"367","author":"Fentiman","year":"2006","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104962_bib33","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/0008-5472.CAN-23-0485","article-title":"\"Combinatorial treatment with PARP and MAPK inhibitors overcomes phenotype switch-driven drug resistance in advanced melanoma.\"","volume":"83","author":"Ferretti","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104962_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-018-0612-8","article-title":"Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response","volume":"10","author":"Francica","year":"2018","journal-title":"Genome Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104962_bib35","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/2159-8290.CD-13-0330","article-title":"SF3B1 mutations are associated with alternative splicing in uveal melanoma","volume":"3","author":"Furney","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104962_bib36","unstructured":"Alexandre Gaubert, Thibault Kervarrec, Henri Montaudi\u00e9, Fanny Burel-Vandenbos, Nathalie Cardot-Leccia, Ilaria Di Mauro, Thibault Fabas, Anne Tallet, Val\u00e9rie Kubiniek, Florence Pedeutour, B\u00e9reng\u00e8re Dadone-Montaudi\u00e9, BRCA1\/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature,Journal of Investigative Dermatology DOI: \u300810.1016\/j.jid.2023.01.014\u3009."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104962_bib37","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11912-024-01524-7","article-title":"Antibody drug conjugates in urological cancers: a review of the current landscape","volume":"26","author":"Ghose","year":"2024","journal-title":"Curr. Oncol. Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104962_bib38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10689-010-9377-y","article-title":"BRCA1 and BRCA2 families and the risk of skin cancer","volume":"9","author":"Ginsburg","year":"2010","journal-title":"Fam. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104962_bib39","unstructured":"GLOBOCAN 2020. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer. \u3008https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf\u3009 (Accessed April 2025)."},{"issue":"7668","key":"10.1016\/j.critrevonc.2025.104962_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumor immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104962_bib41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104962_bib42","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ygyno.2020.12.039","article-title":"The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: who bears the cost?","volume":"160","author":"Goldsberry","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104962_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080354","article-title":"TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma","volume":"8","author":"Griewank","year":"2014","journal-title":"PLOS One"},{"issue":"43","key":"10.1016\/j.critrevonc.2025.104962_bib44","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1038\/sj.onc.1209874","article-title":"The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability","volume":"25","author":"Gudmundsdottir","year":"2006","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104962_bib45","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/bjd.13626","article-title":"Skin cancer risk in BRCA1\/2 mutation carriers","volume":"172","author":"Gumaste","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104962_bib46","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/2159-8290.CD-14-0173","article-title":"Metabolic dysregulation in melanoma: cause or consequence?","volume":"4","author":"Haq","year":"2014","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104962_bib47","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1\u03b1 and MITF","volume":"23","author":"Haq","year":"2013","journal-title":"Cancer Cell"},{"issue":"7653","key":"10.1016\/j.critrevonc.2025.104962_bib48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104962_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination\u2013related gene mutations across multiple cancer types","author":"Heeke","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104962_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275015","article-title":"Progression-free survival and overall survival after BRCA1\/2-associated epithelial ovarian cancer: a matched cohort study","volume":"17","author":"Heemskerk-Gerritsen","year":"2022","journal-title":"PLOS One"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104962_bib51","first-page":"433","article-title":"High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families","volume":"56","author":"Helgadottir","year":"2019","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104962_bib52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2014.07.018","article-title":"Vulnerabilities of mutant SWI\/SNF complexes in cancer","volume":"26","author":"Helming","year":"2014","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104962_bib53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc1092","article-title":"Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma","volume":"3","author":"Hendrix","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104962_bib54","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-015-0581-2","article-title":"Vemurafenib resistance reprograms melanoma cells towards glutamine dependence","volume":"13","author":"Hernandez-Davies","year":"2015","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104962_bib55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104962_bib56","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104962_bib57","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/0008-5472.CAN-07-2491","article-title":"In vivo switching of human melanoma cells between proliferative and invasive states","volume":"68","author":"Hoek","year":"2008","journal-title":"Cancer Res."},{"issue":"6122","key":"10.1016\/j.critrevonc.2025.104962_bib58","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"issue":"6122","key":"10.1016\/j.critrevonc.2025.104962_bib59","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104962_bib60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104962_bib61","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/bjc.2012.483","article-title":"Hereditary breast cancer study group. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers","volume":"107","author":"Iqbal","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104962_bib62","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0959-8049(99)00135-5","article-title":"Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers","volume":"35","author":"Johannsson","year":"1999","journal-title":"Eur. J. Cancer"},{"issue":"7766","key":"10.1016\/j.critrevonc.2025.104962_bib63","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-019-1382-1","article-title":"Tumour lineage shapes BRCA-mediated phenotypes","volume":"571","author":"Jonsson","year":"2019","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104962_bib64","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","article-title":"\"Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.\"","volume":"2","author":"Juvekar","year":"2012","journal-title":"Cancer Discov."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104962_bib65","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1016\/j.febslet.2010.07.057","article-title":"Collaboration and competition between DNA double-strand break repair pathways","volume":"584","author":"Kass","year":"2010","journal-title":"FEBS Lett."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104962_bib66","article-title":"Phase II study of niraparib in patients with advanced melanoma with homologous recombination pathway gene mutations","author":"Kevin B","year":"2025","journal-title":"JCO Precis Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104962_bib67","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.annonc.2020.10.602","article-title":"Mutation clearance and complete radiologic resolution of immunotherapy-relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency","volume":"32","author":"Khaddour","year":"2021","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104962_bib68","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jid.2021.01.024","article-title":"Prevalence of homologous recombination pathway gene mutations in melanoma: rationale for a new targeted therapeutic approach","volume":"141","author":"Kim","year":"2021","journal-title":"J. Investig. Dermatol."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104962_bib69","doi-asserted-by":"crossref","first-page":"8412","DOI":"10.3390\/ijms23158412","article-title":"PARP inhibitors: clinical limitations and recent attempts to overcome them","volume":"23","author":"Kim","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104962_bib70","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","article-title":"A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors","volume":"4","author":"Konieczkowski","year":"2014","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104962_bib71","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"7432","key":"10.1016\/j.critrevonc.2025.104962_bib72","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature11863","article-title":"Fanconi anaemia and the repair of watson and crick DNA crosslinks","volume":"493","author":"Kottemann","year":"2013","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104962_bib73","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104962_bib74","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3390\/cells10020286","article-title":"PARP1 as a marker of an aggressive clinical phenotype in cutaneous melanoma\u2014a clinical and an in vitro study","volume":"10","author":"Kupczyk","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104962_bib75","doi-asserted-by":"crossref","DOI":"10.1186\/s40170-017-0168-x","article-title":"Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities","volume":"5","author":"Lanning","year":"2017","journal-title":"Cancer Metab."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104962_bib76","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.annonc.2020.11.006","article-title":"Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report","volume":"32","author":"Lau","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104962_bib77","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10555-017-9661-5","article-title":"Identification, genetic testing, and management of hereditary melanoma","volume":"36","author":"Leachman","year":"2017","journal-title":"Cancer Metastas.. Rev."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104962_bib78","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/medicina57090905","article-title":"BRCA genes and related cancers: a meta-analysis from epidemiological cohort studies","volume":"57","author":"Lee","year":"2021","journal-title":"Medicina"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104962_bib79","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2012.146","article-title":"Germline BRCA1 mutations increase prostate cancer risk","volume":"106","author":"Leongamornlert","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104962_bib80","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.molcel.2010.11.020","article-title":"Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma","volume":"40","author":"Levy","year":"2010","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104962_bib81","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","article-title":"The cGAS\u2013cGAMP\u2013STING pathway connects DNA damage to inflammation, senescence, and cancer","volume":"215","author":"Li","year":"2018","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104962_bib82","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.tibs.2012.06.007","article-title":"Links between genome integrity and BRCA1 tumor suppression","volume":"37","author":"Li","year":"2012","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.critrevonc.2025.104962_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115329","article-title":"A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer","volume":"206","author":"Li","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104962_bib84","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104962_bib85","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1073\/pnas.1409563112","article-title":"Loss of autophagy causes a synthetic lethal deficiency in DNA repair","volume":"112","author":"Liu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104962_bib86","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104962_bib87","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104962_bib88","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1172\/JCI70454","article-title":"Targeting ER stress\u2013induced autophagy overcomes BRAF inhibitor resistance in melanoma","volume":"124","author":"Ma","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104962_bib89","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2159-8290.CD-12-0313","article-title":"Elucidating distinct roles for NF1 in melanomagenesis","volume":"3","author":"Maertens","year":"2013","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104962_bib90","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","article-title":"Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry","volume":"155","author":"Maniotis","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104962_bib91","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ng.2674","article-title":"Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3","volume":"45","author":"Martin","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2025.104962_bib92","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/bs.adgen.2021.08.002","article-title":"PARP inhibitors in hereditary breast and ovarian cancer and other cancers: a review","volume":"108","author":"Mehta","year":"2021","journal-title":"Adv. Genet."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104962_bib93","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104962_bib94","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2012.01.003","article-title":"PTEN in DNA damage repair","volume":"319","author":"Ming","year":"2012","journal-title":"Cancer Lett."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104962_bib95","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104962_bib96","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13053-024-00277-5","article-title":"Hereditary breast cancer clinical research group. The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations","volume":"22","author":"Narod","year":"2024","journal-title":"Hered. Cancer Clin. Pract."},{"key":"10.1016\/j.critrevonc.2025.104962_bib97","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jdcr.2024.04.005","article-title":"Poly (ADP-Ribose) polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification","volume":"48","author":"Nassief","year":"2024","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.critrevonc.2025.104962_bib98","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jdin.2024.07.024","article-title":"Skin cancer risk in patients with BRCA mutations","volume":"17","author":"Navsaria","year":"2024","journal-title":"JAAD Int."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104962_bib99","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/0284186X.2015.1067714","article-title":"Increased risk of Male cancer and identification of a potential prostate cancer cluster region in BRCA2","volume":"55","author":"Nielsen","year":"2016","journal-title":"Acta Oncol."},{"issue":"6377","key":"10.1016\/j.critrevonc.2025.104962_bib100","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","article-title":"A major chromatin regulator determines resistance of tumor cells to t cell\u2013mediated killing","volume":"359","author":"Pan","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104962_bib101","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41416-021-01599-0","article-title":"Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer","volume":"126","author":"Parkes","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104962_bib102","unstructured":"Petrucelli N., Daly M.B., Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [Updated 2025 Mar 20]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Bookshelf ID: NBK1247."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104962_bib103","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41698-024-00684-w","article-title":"Efficacy of PARP inhibitor therapy after targeted BRAF\/MEK failure in advanced melanoma","volume":"8","author":"Phillipps","year":"2024","journal-title":"NPJ Precis. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104962_bib104","doi-asserted-by":"crossref","first-page":"7917","DOI":"10.1158\/1078-0432.CCR-08-1223","article-title":"Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors","volume":"14","author":"Plummer","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104962_bib105","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00280-013-2113-1","article-title":"A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation","volume":"71","author":"Plummer","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104962_bib106","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/ng.3934","article-title":"A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer","volume":"49","author":"Polak","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2025.104962_bib107","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13059-019-1867-0","article-title":"Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents","volume":"20","author":"P\u00f3ti","year":"2019","journal-title":"Genome Biol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104962_bib108","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1634\/theoncologist.12-9-1114","article-title":"Temozolomide for the treatment of metastatic melanoma: a systematic review","volume":"12","author":"Quirt","year":"2007","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104962_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100152","article-title":"New insights into melanoma tumor syndromes","volume":"2","author":"Rashid","year":"2022","journal-title":"JID Innov."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104962_bib110","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1158\/2159-8290.CD-17-0741","article-title":"A unified approach to targeting the lysosome's degradative and growth signaling roles","volume":"7","author":"Rebecca","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104962_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00369-2","article-title":"Title: niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial","author":"Reiss","year":"2022","journal-title":"J. Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104962_bib112","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3390\/diagnostics11081341","article-title":"Unraveling the wide spectrum of melanoma biomarkers","volume":"11","author":"Revythis","year":"2021","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104962_bib113","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cell.2010.04.020","article-title":"A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth","volume":"141","author":"Roesch","year":"2010","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104962_bib114","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104962_bib115","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1038\/ncomms8103","article-title":"Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing","volume":"6","author":"Salton","year":"2015","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104962_bib116","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1073\/pnas.0808263106","article-title":"Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor","volume":"106","author":"Segura","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104962_bib117","first-page":"673","article-title":"Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: a concise review","volume":"22","author":"Serman","year":"2022","journal-title":"Bosn. J. Basic Med. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104962_bib118","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104962_bib119","first-page":"775","article-title":"Epigenetic regulation of cancer testis antigens in human melanoma: implications for immunotherapy","volume":"92","author":"Sigalotti","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104962_bib120","first-page":"53","article-title":"Melanoma resistance to treatment: role of melanin pigment","volume":"996","author":"Slominski","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104962_bib121","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.08.038","article-title":"Hereditary melanoma: update on syndromes and management: genetics of familial atypical multiple mole melanoma syndrome","volume":"74","author":"Soura","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.critrevonc.2025.104962_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1234973","article-title":"PARP inhibitors combined with radiotherapy: are we ready?","volume":"14","author":"Sun","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104962_bib123","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104962_bib124","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","article-title":"Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress","volume":"33","author":"Tsoi","year":"2018","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104962_bib125","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41589-019-0291-9","article-title":"Mitochondrial metabolism promotes adaptation to proteotoxic stress","volume":"15","author":"Tsvetkov","year":"2019","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104962_bib126","first-page":"2126","article-title":"BRCA1 dysfunction in sporadic basal-like breast cancer","volume":"23","author":"Turner","year":"2004","journal-title":"Oncogene"},{"issue":"6178","key":"10.1016\/j.critrevonc.2025.104962_bib127","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1126\/science.1252230","article-title":"Cancer suppression by BRCA1 and BRCA2","volume":"343","author":"Venkitaraman","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2025.104962_bib128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/164_2017_17","article-title":"Mechanisms of drug resistance in melanoma","volume":"249","author":"Winder","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104962_bib129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2013.220","article-title":"Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies","volume":"22","author":"Workenhe","year":"2014","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.critrevonc.2025.104962_bib130","doi-asserted-by":"crossref","DOI":"10.1177\/1179554921996288","article-title":"The synergistic effect of PARP inhibitors and immune checkpoint inhibitors","volume":"15","author":"Wu","year":"2021","journal-title":"Clin. Med. Insights Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104962_bib131","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.molcel.2006.05.022","article-title":"Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2","volume":"22","author":"Xia","year":"2006","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104962_bib132","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","article-title":"Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104962_bib133","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/jid.2014.416","article-title":"Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival","volume":"135","author":"Yin","year":"2015","journal-title":"J. Investig. Dermatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104962_bib134","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr. Mol. Pharmacol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104962_bib135","doi-asserted-by":"crossref","first-page":"688","DOI":"10.6004\/jnccn.2022.7102","article-title":"Determining PARP inhibition as a treatment strategy in melanoma based on homologous recombination Deficiency\u2013Related loss of heterozygosity","volume":"21","author":"Zhou","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104962_bib136","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41419-023-06303-z","article-title":"Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2025.104962_bib137","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1038\/ncomms7051","article-title":"The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors","volume":"6","author":"Zingg","year":"2015","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104962_bib138","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.3390\/jcm10163760","article-title":"Familial melanoma and susceptibility genes: a review of the most common clinical and dermoscopic phenotypic aspect, associated malignancies and practical tips for management","volume":"10","author":"Zocchi","year":"2021","journal-title":"J. Clin. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:27:51Z","timestamp":1792985271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":138,"alternative-id":["S1040842825003506"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104962","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive analysis of BRCA1\/2 mutations, \u201cBRCAness\u201d and PARP inhibitors in melanoma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104962"}}